Lista de obras - Rocío García-Carbonero

A critical review of HER2-positive gastric cancer evaluation and treatment: from trastuzumab, and beyond

artículo científico publicado en 2014

A phase I trial of daily oral 4'- N -benzoyl-staurosporine in combination with protracted continuous infusion 5-fluorouracil in patients with advanced solid malignancies.

artículo científico publicado en 2004

A phase II and pharmacokinetic study of ecteinascidin 743 in patients with gastrointestinal stromal tumors.

artículo científico publicado en 2002

A randomized phase II study to compare oxaliplatin plus 5-fluorouracil and leucovorin (FOLFOX4) versus oxaliplatin plus raltitrexed (TOMOX) as first-line chemotherapy for advanced colorectal cancer

artículo científico publicado en 2012

An open-label phase II study evaluating the safety and efficacy of ramucirumab combined with mFOLFOX-6 as first-line therapy for metastatic colorectal cancer.

artículo científico publicado en 2014

Analysis of Angiogenesis Biomarkers for Ramucirumab Efficacy in Patients with Metastatic Colorectal Cancer from RAISE, a Global, Randomized, Double-Blind, Phase III Study

artículo científico publicado en 2017

Antibiotics and growth factors in the management of fever and neutropenia in cancer patients.

artículo científico publicado en 2002

Baseline carcinoembryonic antigen as a predictive factor of ramucirumab efficacy in RAISE, a second-line metastatic colorectal carcinoma phase III trial

artículo científico publicado en 2017

Clinical management of regorafenib in the treatment of patients with advanced colorectal cancer

artículo científico publicado en 2014

Comprehensive Plasma Metabolomic Profile of Patients with Advanced Neuroendocrine Tumors (NETs). Diagnostic and Biological Relevance

artículo científico publicado en 2021

Correction: Dasatinib, a Src inhibitor, sensitizes liver metastatic colorectal carcinoma to oxaliplatin in tumors with high levels of phospho-Src

artículo científico publicado en 2016

Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins.

artículo científico publicado en 2002

DICER1, DROSHA and miRNAs in patients with non-small cell lung cancer: implications for outcomes and histologic classification.

artículo científico publicado en 2013

Dasatinib, a Src inhibitor, sensitizes liver metastatic colorectal carcinoma to oxaliplatin in tumors with high levels of phospho-Src

scientific article published on 20 April 2016

Description of the genetic variants identified in a cohort of patients diagnosed with localized anal squamous cell carcinoma and treated with panitumumab

artículo científico publicado en 2021

Design and Validation of the GI-NEC Score to Prognosticate Overall Survival in Patients With High-Grade Gastrointestinal Neuroendocrine Carcinomas.

artículo científico publicado en 2017

Dynamic molecular analysis and clinical correlates of tumor evolution within a phase II trial of panitumumab-based therapy in metastatic colorectal cancer.

artículo científico publicado en 2017

ENETS Consensus Guidelines for High-Grade Gastroenteropancreatic Neuroendocrine Tumors and Neuroendocrine Carcinomas.

artículo científico

ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms. Systemic Therapy 2: Chemotherapy

artículo científico publicado en 2017

ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Systemic Therapy - Biotherapy and Novel Targeted Agents.

artículo científico publicado en 2017

ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Pre- and Perioperative Therapy in Patients with Neuroendocrine Tumors

artículo científico publicado en 2017

Efficacy of trifluridine and tipiracil (TAS-102) versus placebo, with supportive care, in a randomized, controlled trial of patients with metastatic colorectal cancer from Spain: results of a subgroup analysis of the phase 3 RECOURSE trial

scientific article published on 21 July 2016

Epigenetic EGFR Gene Repression Confers Sensitivity to Therapeutic BRAFV600E Blockade in Colon Neuroendocrine Carcinomas

scientific article published on 31 October 2019

Erratum to: Equity, barriers and cancer disparities: study of the Spanish Society of Medical Oncology on the access to oncologic drugs in the Spanish Regions.

artículo científico publicado en 2017

Exposure-response relationship of ramucirumab in patients with advanced second-line colorectal cancer: exploratory analysis of the RAISE trial

artículo científico publicado en 2017

Expression of EGFR, HER-2/neu and KIT in germ cell tumours.

artículo científico publicado en 2010

Favorable prognosis after late relapse of Hodgkin's disease

artículo científico publicado en 1998

Figitumumab in patients with refractory metastatic colorectal cancer previously treated with standard therapies: a nonrandomized, open-label, phase II trial

artículo científico publicado en 2014

GATA4 loss in the septum transversum mesenchyme promotes liver fibrosis in mice

artículo científico publicado en 2014

Gastroenteropancreatic neuroendocrine tumors: current perspectives and future challenges

artículo científico publicado en 2014

Gene expression profile predictive of response to chemotherapy in metastatic colorectal cancer.

artículo científico publicado en 2015

Granulocyte colony-stimulating factor in the treatment of high-risk febrile neutropenia: a multicenter randomized trial.

artículo científico publicado en 2001

Guidelines for biomarker testing in colorectal carcinoma (CRC): a national consensus of the Spanish Society of Pathology (SEAP) and the Spanish Society of Medical Oncology (SEOM).

artículo científico publicado en 2012

Health-related quality of life in well-differentiated metastatic gastroenteropancreatic neuroendocrine tumors.

artículo científico publicado en 2015

High-dose cyclophosphamide + carboplatin and interleukin-2 (IL-2) activated autologous stem cell transplantation followed by maintenance IL-2 therapy in metastatic breast carcinoma - a phase II study

artículo científico publicado en 2000

Identification of oxidative stress related proteins as biomarkers for lung cancer and chronic obstructive pulmonary disease in bronchoalveolar lavage.

artículo científico publicado en 2013

Identification of proteomic signatures associated with lung cancer and COPD.

artículo científico publicado en 2013

Imaging approaches to assess the therapeutic response of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): current perspectives and future trends of an exciting field in development

artículo científico publicado en 2015

Immunohistochemical assessment of Pax8 expression during pancreatic islet development and in human neuroendocrine tumors

artículo científico publicado en 2011

Incidence, patterns of care and prognostic factors for outcome of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): results from the National Cancer Registry of Spain (RGETNE).

artículo científico publicado en 2010

Inhibiting PI3K as a therapeutic strategy against cancer

scientific article published on September 2009

Inhibition of HSP90 molecular chaperones: moving into the clinic

artículo científico publicado en 2013

Is regorafenib providing clinically meaningful benefits to pretreated patients with metastatic colorectal cancer?

artículo científico publicado en 2016

Liquid biopsy detects early molecular response and predicts benefit to first-line chemotherapy plus cetuximab in metastatic colorectal cancer: PLATFORM-B study

artículo científico publicado en 2022

Management of controversial gastroenteropancreatic neuroendocrine tumour clinical situations with somatostatin analogues: results of a Delphi questionnaire panel from the NETPraxis program

artículo científico publicado en 2016

MiR-107 and miR-99a-3p predict chemotherapy response in patients with advanced colorectal cancer

artículo científico publicado en 2014

MicroRNA clusters: dysregulation in lung adenocarcinoma and COPD.

artículo científico publicado en 2014

MicroRNA-dependent regulation of transcription in non-small cell lung cancer

artículo científico publicado en 2014

Molecular biology of neuroendocrine tumors: from pathways to biomarkers and targets

artículo científico publicado en 2014

Neuroendocrine Tumor Heterogeneity Adds Uncertainty to the World Health Organization 2010 Classification: Real-World Data from the Spanish Tumor Registry (R-GETNE).

artículo científico publicado en 2018

Open-label, multicentre expansion cohort to evaluate imgatuzumab in pre-treated patients with KRAS-mutant advanced colorectal carcinoma

artículo científico publicado en 2013

Optimization of RAS/BRAF Mutational Analysis Confirms Improvement in Patient Selection for Clinical Benefit to Anti-EGFR Treatment in Metastatic Colorectal Cancer.

artículo científico publicado en 2017

Optimizing Somatostatin Analog Use in Well or Moderately Differentiated Gastroenteropancreatic Neuroendocrine Tumors.

artículo científico publicado en 2017

Outpatient therapy with oral ofloxacin for patients with low risk neutropenia and fever: a prospective, randomized clinical trial.

artículo científico publicado en 1999

Oxidized lipids in the metabolic profiling of neuroendocrine tumors - Analytical challenges and biological implications

scientific article published on 28 May 2020

PD-012Analysis of patients ≥75 years in the open-label phase 3b CONSIGN trial of regorafenib in previously treated metastatic colorectal cancer (mCRC).

artículo científico publicado en 2016

PD-025RECOURSE trial: impact of adverse events on quality of life and duration of TAS-102 (trifluridine and tipiracil) treatment.

artículo científico publicado en 2016

PD-029Baseline carcinoembryonic antigen (CEA) as a predictive factor of ramucirumab efficacy in RAISE, a second-line metastatic colorectal carcinoma (mCRC) phase 3 trial.

artículo científico publicado en 2016

PDGFRα/β and VEGFR2 polymorphisms in colorectal cancer: incidence and implications in clinical outcome

artículo científico publicado en 2012

Patient selection in high-dose chemotherapy trials: relevance in high-risk breast cancer ⬇️

artículo científico publicado el 1 de octubre de 1997

Pax8 Detection in Well-Differentiated Pancreatic Endocrine Tumors

artículo científico publicado en 2011

Pazopanib in pretreated advanced neuroendocrine tumors: a phase II, open-label trial of the Spanish Task Force Group for Neuroendocrine Tumors (GETNE).

artículo científico publicado en 2015

Phase 1 study of cetuximab in combination with 5-fluorouracil, cisplatin, and radiotherapy in patients with locally advanced anal canal carcinoma

article published in 2013

Phase 1 study of intravenous administration of the chimeric adenovirus enadenotucirev in patients undergoing primary tumor resection.

artículo científico publicado en 2017

Phase I clinical trial of recombinant human endostatin administered as a short intravenous infusion repeated daily.

artículo científico publicado en 2002

Phase I/II study of gefitinib and capecitabine in patients with colorectal cancer.

artículo científico publicado en 2008

Phase II Study of BEZ235 versus Everolimus in Patients with Mammalian Target of Rapamycin Inhibitor-Naïve Advanced Pancreatic Neuroendocrine Tumors

artículo científico publicado en 2017

Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy.

artículo científico publicado en 2004

Phase II study of trastuzumab and cisplatin as first-line therapy in patients with HER2-positive advanced gastric or gastroesophageal junction cancer

artículo científico publicado en 2011

Phase II trial of cisplatin and gemcitabine in advanced squamous-cell carcinoma of the head and neck.

artículo científico publicado en 1998

Plasma pharmacokinetics and bioavailability of 1-(2-chloroethyl)-3-sarcosinamide-1-nitrosourea after intravenous and oral administration to mice and dogs.

artículo científico publicado en 2001

Primary cisplatin, methotrexate and vinblastine chemotherapy with selective bladder preservation for muscle invasive carcinoma of the bladder: long-term followup of a prospective study

scientific article published on 01 June 2002

Prognostic factors and long-term outcome of pancreatic neuroendocrine neoplasms: Ki-67 index shows a greater impact on survival than disease stage. The large experience of the Spanish National Tumor Registry (RGETNE).

artículo científico publicado en 2013

Prognostic relevance of Src activation in stage II-III colon cancer

artículo científico publicado en 2017

Prognostic relevance of estrogen receptor-α Ser167 phosphorylation in stage II-III colon cancer patients.

artículo científico publicado en 2014

Prognostic value of KIT expression in small cell lung cancer

artículo científico publicado en 2007

Proxies of quality of life in metastatic colorectal cancer: analyses in the RECOURSE trial

artículo científico publicado en 2017

Ramucirumab Clinical Development: an Emerging Role in Gastrointestinal Tumors

artículo científico publicado en 2016

Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with FOLFOX and Bevacizumab for First-Line Metastatic Colorectal Cancer.

artículo científico publicado en 2017

Randomized trial of TAS-102 for refractory metastatic colorectal cancer

artículo científico publicado en 2015

Recent Therapeutic Advances and Change in Treatment Paradigm of Patients with Merkel Cell Carcinoma

scientific article published on 08 April 2019

SEOM clinical guidelines for diagnosis and treatment of metastatic colorectal cancer 2015.

artículo científico publicado en 2015

SEOM clinical guidelines for the diagnosis and treatment of gastric adenocarcinoma

artículo científico publicado en 2012

SEOM clinical guidelines for the diagnosis and treatment of gastroenteropancreatic and bronchial neuroendocrine neoplasms (NENs) (2018)

artículo científico publicado en 2018

SEOM clinical guidelines for the diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) 2014

artículo científico publicado en 2014

SEOM clinical guidelines for the diagnosis and treatment of gastroenteropancreatic neuroendocrine tumours (GEP NETS)

artículo científico publicado en 2011

SEOM clinical guidelines for the treatment of advanced colorectal cancer

artículo científico publicado en 2010

SEOM clinical guidelines for the treatment of advanced colorectal cancer 2013.

artículo científico publicado en 2013

SEOM/SERAM consensus statement on radiological diagnosis, response assessment and follow-up in colorectal cancer

artículo científico publicado en 2016

Safety and Activity of the First-in-Class Sym004 Anti-EGFR Antibody Mixture in Patients with Refractory Colorectal Cancer.

artículo científico publicado en 2015

Safety and efficacy of nintedanib for the treatment of metastatic colorectal cancer

artículo científico publicado en 2017

Sorafenib and bevacizumab combination targeted therapy in advanced neuroendocrine tumour: a phase II study of Spanish Neuroendocrine Tumour Group (GETNE0801)

artículo científico publicado en 2013

Sorafenib in Combination with Oxaliplatin, Leucovorin, and Fluorouracil (Modified FOLFOX6) as First-line Treatment of Metastatic Colorectal Cancer: The RESPECT Trial

artículo científico publicado en 2013

Spanish Society of Medical Oncology consensus for the use of haematopoietic colony-stimulating factors in cancer patients.

artículo científico publicado en 2009

Spinophilin loss correlates with poor patient prognosis in advanced stages of colon carcinoma.

artículo científico publicado en 2013

Subgroup analysis in RAISE: a randomized, double-blind phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab or placebo in patients with metastatic colorectal carcinoma progression

artículo científico publicado en 2016

Sunitinib and Evofosfamide (TH-302) in Systemic Treatment-Naïve Patients with Grade 1/2 Metastatic Pancreatic Neuroendocrine Tumors: The GETNE-1408 Trial

artículo científico publicado en 2021

Systemic chemotherapy in the management of malignant peritoneal mesothelioma.

artículo científico publicado en 2006

Systemic therapeutic strategies for GEP-NETS: what can we expect in the future?

artículo científico

Targeting tyrosine kinase receptors in hepatocellular carcinoma.

artículo científico publicado en 2013

Telotristat ethyl in carcinoid syndrome: safety and efficacy in the TELECAST phase 3 trial

artículo científico publicado en 2018

The Antiproliferative Role of Lanreotide in Controlling Growth of Neuroendocrine Tumors: A Systematic Review

artículo científico publicado en 2017

The European Medicines Agency review of Tegafur/Gimeracil/Oteracil (Teysuno™) for the treatment of advanced gastric cancer when given in combination with cisplatin: summary of the Scientific Assessment of the Committee for medicinal products [...]

artículo científico publicado en 2011

The European medicines agency review of abiraterone for the treatment of metastatic castration-resistant prostate cancer in adult men after docetaxel chemotherapy and in chemotherapy-naive disease: summary of the scientific assessment of the committ

artículo científico publicado en 2013

The safety and efficacy of ramucirumab for the treatment of metastatic colorectal cancer.

artículo científico publicado en 2016

Therapy innovations: tyrosine kinase inhibitors for the treatment of pancreatic neuroendocrine tumors.

artículo científico publicado en 2011

Translational research in neuroendocrine tumors: pitfalls and opportunities

artículo científico publicado en 2016

Updated guidelines for biomarker testing in colorectal carcinoma: a national consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology

artículo científico publicado en 2014

Well-Differentiated Grade 2, Type 3 Gastrointestinal Neuroendocrine Tumour with Bilateral Metastatic Ovarian Involvement: Report of an Unusual Case.

artículo científico publicado en 2016

Lista de obras de Rocío García-Carbonero

A critical review of HER2-positive gastric cancer evaluation and treatment: from trastuzumab, and beyond

A phase I trial of daily oral 4'- N -benzoyl-staurosporine in combination with protracted continuous infusion 5-fluorouracil in patients with advanced solid malignancies.

A phase II and pharmacokinetic study of ecteinascidin 743 in patients with gastrointestinal stromal tumors.

A randomized phase II study to compare oxaliplatin plus 5-fluorouracil and leucovorin (FOLFOX4) versus oxaliplatin plus raltitrexed (TOMOX) as first-line chemotherapy for advanced colorectal cancer

An open-label phase II study evaluating the safety and efficacy of ramucirumab combined with mFOLFOX-6 as first-line therapy for metastatic colorectal cancer.

Analysis of Angiogenesis Biomarkers for Ramucirumab Efficacy in Patients with Metastatic Colorectal Cancer from RAISE, a Global, Randomized, Double-Blind, Phase III Study

Antibiotics and growth factors in the management of fever and neutropenia in cancer patients.

Baseline carcinoembryonic antigen as a predictive factor of ramucirumab efficacy in RAISE, a second-line metastatic colorectal carcinoma phase III trial

Clinical management of regorafenib in the treatment of patients with advanced colorectal cancer

Comprehensive Plasma Metabolomic Profile of Patients with Advanced Neuroendocrine Tumors (NETs). Diagnostic and Biological Relevance

Correction: Dasatinib, a Src inhibitor, sensitizes liver metastatic colorectal carcinoma to oxaliplatin in tumors with high levels of phospho-Src

Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins.

DICER1, DROSHA and miRNAs in patients with non-small cell lung cancer: implications for outcomes and histologic classification.

Dasatinib, a Src inhibitor, sensitizes liver metastatic colorectal carcinoma to oxaliplatin in tumors with high levels of phospho-Src

Description of the genetic variants identified in a cohort of patients diagnosed with localized anal squamous cell carcinoma and treated with panitumumab

Design and Validation of the GI-NEC Score to Prognosticate Overall Survival in Patients With High-Grade Gastrointestinal Neuroendocrine Carcinomas.

Dynamic molecular analysis and clinical correlates of tumor evolution within a phase II trial of panitumumab-based therapy in metastatic colorectal cancer.

ENETS Consensus Guidelines for High-Grade Gastroenteropancreatic Neuroendocrine Tumors and Neuroendocrine Carcinomas.

ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms. Systemic Therapy 2: Chemotherapy

ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Systemic Therapy - Biotherapy and Novel Targeted Agents.

ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Pre- and Perioperative Therapy in Patients with Neuroendocrine Tumors

Efficacy of trifluridine and tipiracil (TAS-102) versus placebo, with supportive care, in a randomized, controlled trial of patients with metastatic colorectal cancer from Spain: results of a subgroup analysis of the phase 3 RECOURSE trial

Epigenetic EGFR Gene Repression Confers Sensitivity to Therapeutic BRAFV600E Blockade in Colon Neuroendocrine Carcinomas

Erratum to: Equity, barriers and cancer disparities: study of the Spanish Society of Medical Oncology on the access to oncologic drugs in the Spanish Regions.

Exposure-response relationship of ramucirumab in patients with advanced second-line colorectal cancer: exploratory analysis of the RAISE trial

Expression of EGFR, HER-2/neu and KIT in germ cell tumours.

Favorable prognosis after late relapse of Hodgkin's disease

Figitumumab in patients with refractory metastatic colorectal cancer previously treated with standard therapies: a nonrandomized, open-label, phase II trial

GATA4 loss in the septum transversum mesenchyme promotes liver fibrosis in mice

Gastroenteropancreatic neuroendocrine tumors: current perspectives and future challenges

Gene expression profile predictive of response to chemotherapy in metastatic colorectal cancer.

Granulocyte colony-stimulating factor in the treatment of high-risk febrile neutropenia: a multicenter randomized trial.

Guidelines for biomarker testing in colorectal carcinoma (CRC): a national consensus of the Spanish Society of Pathology (SEAP) and the Spanish Society of Medical Oncology (SEOM).

Health-related quality of life in well-differentiated metastatic gastroenteropancreatic neuroendocrine tumors.

High-dose cyclophosphamide + carboplatin and interleukin-2 (IL-2) activated autologous stem cell transplantation followed by maintenance IL-2 therapy in metastatic breast carcinoma - a phase II study

Identification of oxidative stress related proteins as biomarkers for lung cancer and chronic obstructive pulmonary disease in bronchoalveolar lavage.

Identification of proteomic signatures associated with lung cancer and COPD.

Imaging approaches to assess the therapeutic response of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): current perspectives and future trends of an exciting field in development

Immunohistochemical assessment of Pax8 expression during pancreatic islet development and in human neuroendocrine tumors

Incidence, patterns of care and prognostic factors for outcome of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): results from the National Cancer Registry of Spain (RGETNE).

Inhibiting PI3K as a therapeutic strategy against cancer

Inhibition of HSP90 molecular chaperones: moving into the clinic

Is regorafenib providing clinically meaningful benefits to pretreated patients with metastatic colorectal cancer?

Liquid biopsy detects early molecular response and predicts benefit to first-line chemotherapy plus cetuximab in metastatic colorectal cancer: PLATFORM-B study

Management of controversial gastroenteropancreatic neuroendocrine tumour clinical situations with somatostatin analogues: results of a Delphi questionnaire panel from the NETPraxis program

MiR-107 and miR-99a-3p predict chemotherapy response in patients with advanced colorectal cancer

MicroRNA clusters: dysregulation in lung adenocarcinoma and COPD.

MicroRNA-dependent regulation of transcription in non-small cell lung cancer

Molecular biology of neuroendocrine tumors: from pathways to biomarkers and targets

Neuroendocrine Tumor Heterogeneity Adds Uncertainty to the World Health Organization 2010 Classification: Real-World Data from the Spanish Tumor Registry (R-GETNE).

Open-label, multicentre expansion cohort to evaluate imgatuzumab in pre-treated patients with KRAS-mutant advanced colorectal carcinoma

Optimization of RAS/BRAF Mutational Analysis Confirms Improvement in Patient Selection for Clinical Benefit to Anti-EGFR Treatment in Metastatic Colorectal Cancer.

Optimizing Somatostatin Analog Use in Well or Moderately Differentiated Gastroenteropancreatic Neuroendocrine Tumors.

Outpatient therapy with oral ofloxacin for patients with low risk neutropenia and fever: a prospective, randomized clinical trial.

Oxidized lipids in the metabolic profiling of neuroendocrine tumors - Analytical challenges and biological implications

PD-012Analysis of patients ≥75 years in the open-label phase 3b CONSIGN trial of regorafenib in previously treated metastatic colorectal cancer (mCRC).

PD-025RECOURSE trial: impact of adverse events on quality of life and duration of TAS-102 (trifluridine and tipiracil) treatment.

PD-029Baseline carcinoembryonic antigen (CEA) as a predictive factor of ramucirumab efficacy in RAISE, a second-line metastatic colorectal carcinoma (mCRC) phase 3 trial.

PDGFRα/β and VEGFR2 polymorphisms in colorectal cancer: incidence and implications in clinical outcome

Patient selection in high-dose chemotherapy trials: relevance in high-risk breast cancer ⬇️

Pax8 Detection in Well-Differentiated Pancreatic Endocrine Tumors

Pazopanib in pretreated advanced neuroendocrine tumors: a phase II, open-label trial of the Spanish Task Force Group for Neuroendocrine Tumors (GETNE).

Phase 1 study of cetuximab in combination with 5-fluorouracil, cisplatin, and radiotherapy in patients with locally advanced anal canal carcinoma

Phase 1 study of intravenous administration of the chimeric adenovirus enadenotucirev in patients undergoing primary tumor resection.

Phase I clinical trial of recombinant human endostatin administered as a short intravenous infusion repeated daily.

Phase I/II study of gefitinib and capecitabine in patients with colorectal cancer.

Phase II Study of BEZ235 versus Everolimus in Patients with Mammalian Target of Rapamycin Inhibitor-Naïve Advanced Pancreatic Neuroendocrine Tumors

Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy.

Phase II study of trastuzumab and cisplatin as first-line therapy in patients with HER2-positive advanced gastric or gastroesophageal junction cancer

Phase II trial of cisplatin and gemcitabine in advanced squamous-cell carcinoma of the head and neck.

Plasma pharmacokinetics and bioavailability of 1-(2-chloroethyl)-3-sarcosinamide-1-nitrosourea after intravenous and oral administration to mice and dogs.

Primary cisplatin, methotrexate and vinblastine chemotherapy with selective bladder preservation for muscle invasive carcinoma of the bladder: long-term followup of a prospective study

Prognostic factors and long-term outcome of pancreatic neuroendocrine neoplasms: Ki-67 index shows a greater impact on survival than disease stage. The large experience of the Spanish National Tumor Registry (RGETNE).

Prognostic relevance of Src activation in stage II-III colon cancer

Prognostic relevance of estrogen receptor-α Ser167 phosphorylation in stage II-III colon cancer patients.

Prognostic value of KIT expression in small cell lung cancer

Proxies of quality of life in metastatic colorectal cancer: analyses in the RECOURSE trial

Ramucirumab Clinical Development: an Emerging Role in Gastrointestinal Tumors

Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with FOLFOX and Bevacizumab for First-Line Metastatic Colorectal Cancer.